Skip to main content

Table 1 Baseline characteristics of patients in the PLATO study, by treatment group*[7]

From: Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand

Characteristic Ticagrelor group (N = 9333) Clopidogrel group (N = 9291)
Age — median (range) 62.0 (19–97) 62.0 (21–94)
Female sex — no. (%) 2655 (28.4) 2633 (28.3)
BMI — median (range) 27 (13–68) 27 (13–70)
Cardiovascular risk factor — no./total no. (%)   
Habitual smoker 3360 (36.0) 3318 (35.7)
Hypertension 6139 (65.8) 6044 (65.1)
Dyslipidemia 4347 (46.6) 4342 (46.7)
Diabetes mellitus 2326 (24.9) 2336 (25.1)
Other medical history — no./total no. (%)   
MI 1900 (20.4) 1924 (20.7)
Percutaneous coronary intervention 1272 (13.6) 1220 (13.1)
Congestive heart failure 513 (5.5) 537 (5.8)
Final diagnosis of ACS — no./total no. (%)   
ST-elevation MI 3496 (37.5) 3530 (38.0)
Non–ST-elevation MI 4005 (42.9) 3950 (42.5)
Unstable angina 1549 (16.6) 1563 (16.8)
Other diagnosis or missing data 283 (3.0) 248 (2.7)
  1. *Adapted from PLATO [7].